Health Product InfoWatch, May 2021


Download the alternative format
(PDF format, 409 KB, 7 pages)

Health Products and Food Branch
Marketed Health Products Directorate
Health Product InfoWatch Editorial Team
ISSN: 2368-8025
Cat.: H167-1E-PDF
Pub.: 210000


Health products mentioned in this issue

Pharmaceuticals and biologics

Medical devices

Natural and non-prescription health products


Coronavirus disease (COVID-19)

For the most up-to-date information on COVID-19, please visit the Government of Canada Coronavirus disease (COVID-19) website, which includes a dedicated section for healthcare professionals, and for the health product industry.

The COVID-19 vaccines and treatments portal provides information for consumers, healthcare professionals and researchers on vaccines and treatments authorized for COVID-19, as well as those currently under review.

For information about adverse events following immunization that individuals have reported after receiving a COVID-19 vaccine in Canada please visit the COVID-19 vaccine safety in Canada webpage. This page is updated weekly.

Drug and vaccine authorizations and communications for COVID-19

Recent communications related to authorized COVID-19 vaccines and treatments are highlighted in this section.

Janssen COVID-19 Vaccine

This safety review evaluated the risk of thrombosis in combination with thrombocytopenia associated with Janssen COVID-19 Vaccine. Health Canada's review of the available information concluded that a link is possible. The risk of thrombosis in combination with thrombocytopenia is very rare and the overall benefits of the vaccine in protecting Canadians from COVID-19 outweigh the risk. Health Canada worked with the manufacturer to update the Canadian product monograph for Janssen COVID-19 Vaccine to reflect current knowledge of this safety issue. Health Canada also communicated to vaccine recipients and healthcare professionals about this risk.

Pfizer-BioNTech COVID-19 Vaccine

Health Canada authorized use of the Pfizer-BioNTech COVID-19 Vaccine in children 12 to 15 years of age.

Health Canada authorized more flexible storage conditions for Pfizer-BioNTech COVID-19 Vaccine. Pfizer-BioNTech COVID-19 Vaccine can now be stored at regular refrigerated temperatures (2-8°C) at the point of use for up to one month.

Veklury (remdesivir)

This safety review evaluated the risk of acute kidney injury or acute renal failure associated with Veklury (remdesivir). Health Canada's review could not establish a direct link. The Canadian product monograph for Veklury includes information on kidney toxicity and recommendations on usage. Therefore, the safety information for Veklury is appropriate at this time.

Monthly recap of health product safety information

The following is a list of health product advisories, type I recalls as well as summaries of completed safety reviews published in April 2021 by Health Canada.

For health product advisories related to COVID-19 vaccines and treatments, please see the Drug and vaccine authorizations and communications for COVID-19 section.


Apotex Inc. recalled 2 lots (lot PY1831, expiry 12/2023 and lot RF0410, expiry 05/2024) of APO-Amitriptyline 10 mg tablets (DIN 02403137), after testing identified NDMA, a nitrosamine impurity, above the acceptable limit. The majority of lots tested by Apotex Inc. to date are within the acceptable limit; therefore, patients are not expected to be exposed to levels of NDMA that exceed safe levels for an extended period of time. Patients can continue to take their medication as prescribed by their healthcare provider and do not need to return their medication to their pharmacy.

Certain hand sanitizers that may pose health risks

Health Canada advised Canadians that certain hand sanitizers were recalled because they either contained ingredients that were not permitted by Health Canada, were not properly labelled, were unauthorized, or were missing important information.

Face masks that contain graphene

Health Canada advised Canadians not to use face masks that contain graphene due to the potential risk of inhaling graphene particles. Graphene is a novel nanomaterial reported to have antiviral and antibacterial properties. Health Canada’s preliminary assessment of available research identified that inhaled graphene particles had some potential to cause early lung toxicity in animals. Until the Department completes a thorough scientific assessment, it is taking the precautionary approach of removing graphene-containing face masks from the market while continuing to gather and assess information.

L’il Critters Gummy Vites, vitafusion Fibre Well, and vitafusion MultiVites

Church & Dwight Canada Corp. recalled certain lots of L’il Critters Gummy Vites children’s vitamins, as well as vitafusion Fibre Well and vitafusion MultiVites vitamins for adults, because certain lots may contain metal wire fragments. The affected lots were manufactured within a specific four-day period between October 29 and November 3, 2020. The products were distributed nationally.


SteriMax Inc. recalled OrfenAce 100 mg tablets (DIN 02047535) after testing identified a nitrosamine impurity above what is considered acceptable if the drug were to be taken over a lifetime. Health Canada is advising that there is no immediate risk to patients taking this medication since the potential risk of cancer is with long-term (every day for 70 years) exposure to nitrosamine impurities that exceeds safe levels, which is not what is expected to occur with patients taking the affected medication for a short period of time.

Unauthorized health products

Health Canada advised Canadians about various unauthorized health products being sold at retail locations across Canada or online that may pose serious health risks.

Xeljanz and Xeljanz XR (tofacitinib)

Health Canada is conducting a safety review of Xeljanz and Xeljanz XR (tofacitinib) after a clinical trial identified an increased risk of serious heart-related issues and cancer in trial participants. The clinical trial investigated the long-term safety of Xeljanz and Xeljanz XR at 2 doses (5 mg twice a day and 10 mg twice a day) in patients with rheumatoid arthritis, who were at least 50 years of age and had at least one cardiovascular risk factor. Health Canada is working with the manufacturer to evaluate the available safety information and will inform the public of any new safety findings once the review is completed.

New health product safety information

The following topics have been selected to raise awareness and, in some cases, to stimulate reporting of similar adverse reactions.

Review article

Systemic corticosteroids (including dexamethasone) and pheochromocytoma crisis when administered to patients with identified, suspected or unsuspected pheochromocytoma

Key messages

Dexamethasone is a corticosteroid product with glucocorticoid effects used to treat a wide variety of conditions associated with inflammation.Footnote 1Footnote 2 This includes, but is not limited to, severe allergies, rheumatoid arthritis, various skin and eye conditions, endocrine disorders, respiratory diseases, blood disorders, ulcerative colitis, and some types of blood cancers.

Recently, the Public Health Agency of Canada released a statement from the Clinical Pharmacology Task Group recommending that systemic dexamethasone, at a dose of 6 mg IV for 10 days, should strongly be considered in the treatment of hospitalized patients with COVID-19 who require supplemental oxygen or mechanical ventilation.

Systemic dexamethasone, and other types of corticosteroids, have been reported in the medical literature to trigger pheochromocytoma crisis in patients with identified, suspected or unsuspected pheochromocytoma.Footnote 3Footnote 4Footnote 5Footnote 6Footnote 7Footnote 8Footnote 9Footnote 10

Pheochromocytomas are rare, catecholamine-secreting tumours of the sympathetic nervous system originating from the chromaffin cells of the adrenal medulla.Footnote 3 The clinical presentation may vary, but characteristic signs and symptoms include hypertension, sweating, palpitations, and headache.Footnote 3Footnote 4

Pheochromocytoma crisis is a rare, life-threatening endocrine emergency in which high levels of catecholamines are released from a pheochromocytoma.Footnote 3Footnote 4 This condition causes acute, severe hemodynamic instability that can lead to multi-organ dysfunction. It is often reversible with appropriate treatment, or if the crisis recedes.Footnote 4Footnote 5 Pheochromocytoma crisis can be difficult to diagnose if the patient is not already known to have a pheochromocytoma, as it may mimic other life-threatening conditions.Footnote 3Footnote 4 Prompt confirmation of the diagnosis is likely to improve survival.Footnote 4

Evidence from literature

Cases of pheochromocytoma crisis suspected of being induced by corticosteroids have been reported in the literature. One literature review summarized 25 cases of catecholaminergic crisis in patients with adrenal masses following corticosteroid or cosyntropin administration, 8 of which reported the use of dexamethasone.Footnote 6 The presenting signs and symptoms included hypertension, palpitations, arrhythmias, headache, nausea, vomiting, cardiac ischemia, pulmonary edema and shock. More than 30% of the 25 cases were fatal and most required admission to an intensive care unit. Considerable variability was noted in the type of corticosteroid, dose, route of administration, and time to onset of symptoms. In many cases, pheochromocytoma was undiagnosed prior to corticosteroid administration. Some cases of catecholaminergic crisis were reported in patients following high-dose systemic dexamethasone suppression tests (DST). For these cases, it was suggested that tumour size and the dose used for DST may have played a role in the risk of catecholaminergic crisis. The smallest documented dose of dexamethasone that is suspected of inducing a crisis was 2 mg administered orally (prescribed every 6 hours) and time to onset was 5 hours. 

A Canadian case of unsuspected pheochromocytoma presenting with an adrenergic crisis following systemic dexamethasone administration was reported in the literature.Footnote 7 In this case, a 73-year old man with no previous relevant medical history and no regular medications presented to the emergency room with an acute onset of non-specific, mild epigastric discomfort with nausea, vomiting, orthostatic dizziness and palpitations. The patient was on his third day of treatment with amoxicillin, ibuprofen, and systemic dexamethasone (4 mg daily for 3 days) following a dental procedure. The authors indicated that the clinical course, as well as the documented transient massive release of catecholamine following administration of dexamethasone, strongly pointed to dexamethasone as the trigger for the adrenergic crisis.

As of April 21, 2021, no other suspected cases of pheochromocytoma crisis in association with systemic corticosteroids, including dexamethasone, have been reported in Canada.Footnote * 

Mechanism and conclusion

Although systemic corticosteroids have been implicated in triggering pheochromocytoma crisis, the mechanism remains unclear.Footnote 7Footnote 8 Several mechanisms have been hypothesized including potentiation of the action of catecholamines on peripheral vessels and the heart, potentially leading to vasculopathy, tissue necrosis and hemorrhage. Another hypothesis proposes that increased corticosteroid receptor expression may mediate pheochromocytoma tumour sensitivity to corticosteroids and trigger catecholamine synthesis, production and release.

Evidence from the literature suggests that systemic dexamethasone and other corticosteroids should be avoided in patients with known pheochromocytoma, or in those with an adrenal adenoma without a negative biochemical workup for a pheochromocytoma, as it could precipitate an adrenergic crisis.Footnote 6Footnote 7Footnote 8Footnote 9

Pheochromocytoma crisis should be considered as a differential diagnosis in patients who have been treated with systemic dexamethasone, or other corticosteroid products, and present with severe hemodynamic instability, shock, arrhythmia, cardiac ischemia, or other symptoms suggestive of adrenergic crisis.Footnote 7Footnote 8Footnote 9Footnote 10

Healthcare professionals are encouraged to report to Health Canada any cases of pheochromocytoma crisis suspected to be associated with the use of dexamethasone or other corticosteroid products. This information will support ongoing monitoring of this safety issue.


Footnote 1

Dexamethasone. In: Buckingham R (ed). Martindale: The complete drug reference. [online] London (UK): Pharmaceutical Press: 2019. (accessed 2021 March 24)

Return to footnote 1 referrer

Footnote 2

Corticosteroids: Systemic [CPhA monograph]. In: CPS. [online] Ottawa (ON): Canadian Pharmacists Association; updated August 2018. (accessed 2021 March 24).

Return to footnote 2 referrer

Footnote 3

Castelino T., Elliot M. Pheochromocytoma crisis. In: Lew JI. Clinical management of adrenal tumors. London (UK): IntechOpen; 2017.

Return to footnote 3 referrer

Footnote 4

Whitelaw BC, Prague JK, Mustafa OG, et al. Phaeochromocytoma [corrected] crisis. Clin Endocrinol (Oxf) 2014; 80(1):13-22.

Return to footnote 4 referrer

Footnote 5

Geva GA, Gross DJ, Mazeh H, et al. Adrenocorticotropic hormone secreting pheochromocytoma underlying glucocorticoid induced pheochromocytoma crisis. Case Rep Endocrinol 2018; 2018:3963274.

Return to footnote 5 referrer

Footnote 6

Barrett C, van Uum SH, Lenders JW. Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review. Clin Endocrinol (Oxf) 2015; 83(5):622-8.

Return to footnote 6 referrer

Footnote 7

Dupont MF, Battista MC, Comeau E, et al. Corticosteroid-induced case of a lightning pheochromocytoma crisis: Insight into glucocorticoid receptor expression. Integr Cancer Sci Ther 2016; 3(1):345-8.

Return to footnote 7 referrer

Footnote 8

Rosas AL, Kasperlik-Zaluska AA, Papierska L, et al. Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. Eur J Endocrinol 2008;158(3):423-9.

Return to footnote 8 referrer

Footnote 9

Eagan D, Munoz Pena J, Barb D. SAT-214 Steroid induced pheochromocytoma crisis. J Endocr Soc 2020; 4, Issue Supplement_1.

Return to footnote 9 referrer

Footnote 10

Ibrahim M, Banga S, Venkatapuram S, et al. Transient cardiogenic shock during a crisis of pheochromocytoma triggered by high-dose exogenous corticosteroids. BMJ Case Rep 2015;2015:bcr2014208683. doi: 10.1136/bcr-2014-208683.

Return to footnote 10 referrer

Footnote *

Please note that there may be reports which have been received but not yet processed and entered into the database. New and additional information may be available at a later date.

Return to footnote * referrer

Product monograph updates

The following safety labelling updates, which were recently made to the Canadian product monograph, have been selected for your awareness. A complete list of safety labelling updates for pharmaceuticals is available on Health Canada's Product monograph brand safety updates page. Canadian product monographs can be accessed through Health Canada's Drug Product Database.

Voluven and Volulyte (hydroxyethyl starch)  

The Indications and Clinical use, Contraindications, Warnings and Precautions (Serious Warnings and Precautions Box), Dosage and Administration, and Consumer Information sections of the Canadian product monographs for Voluven and Volulyte, have been updated to further mitigate the risk of renal injury and death.

Key messages for healthcare professionals:Footnote 1Footnote 2


Footnote 1

Voluven (hydroxyethyl starch 130/0.4) [product monograph]. Toronto (ON): Fresenius Kabi Canada Ltd; 2020.

Return to footnote 1 referrer

Footnote 2

Volulyte (hydroxyethyl starch 130/0.4) [product monograph]. Toronto (ON): Fresenius Kabi Canada Ltd; 2020.

Return to footnote 2 referrer

Did you know

The MedEffect e-Notice is a free subscription service that provides email notifications to keep subscribers up to date when Health Canada publishes new safety information, including health product risk communications, public advisories and the Health Product InfoWatch. To better serve Canadians, this system is being upgraded with a modernized new look and feel while also enabling a range of customization features giving subscribers more choice in the type of information they receive and how this information is delivered. The new system is expected to be launched in the coming weeks, with more information to follow on how current subscribers can update their preferences as well as sign up instructions for new subscribers.


This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products. It provides a summary of key health product safety information published in the previous month by Health Canada, as well as a selection of new health product safety information meant to raise awareness. New information contained in this issue is not comprehensive but rather represents a selection of clinically relevant items warranting enhanced dissemination.

Reporting Adverse Reactions

Canada Vigilance Program
Telephone: 1-866-234-2345
Fax or mail: Form available on MedEffect Canada

For more information on how to report an adverse reaction, visit the Adverse Reaction and Medical Device Problem Reporting page.

Helpful links


Your comments are important to us. Let us know what you think by reaching us at

Health Canada
Marketed Health Products Directorate
Address Locator 1906C
Ottawa ON K1A 0K9
Telephone: 613-954-6522
Fax: 613-952-7738


© 2021 Her Majesty the Queen in Right of Canada. This publication may be reproduced without permission provided the source is fully acknowledged. The use of this publication for advertising purposes is prohibited. Health Canada does not assume liability for the accuracy or authenticity of the information submitted in case reports.

Adverse reactions (ARs) to health products are considered to be suspicions, as a definite causal association often cannot be determined. Spontaneous reports of ARs cannot be used to estimate the incidence of ARs because ARs remain underreported and patient exposure is unknown.

Due to time constraints relating to the production of this publication, information published may not reflect the most current information.

Page details

Date modified: